Navigation Links
Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT
Date:11/3/2011

WARRENDALE, Pa., Nov. 3, 2011 /PRNewswire/ -- MEDRAD Interventional, a business of Bayer HealthCare, today announced that five-year data from the THUNDER trial will be presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco. The data will focus on five-year rates of target lesion revascularization comparing the Cotavance® drug eluting balloon (DEB) catheter with Paccocath® Technology to standard balloon angioplasty (POBA) in popliteal arteries of patients with peripheral arterial disease (PAD). Presented by Prof. Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, during the TCT-sponsored symposium, "Drug-Coated Balloons: Clinical Data and Applications," at 2 p.m. PST Nov. 10, the results will continue to build on the long-term clinical experience with the Paccocath® technology, which is available in Europe, but not yet approved in the U.S.

"The only published positive long-term clinical results to date with drug-eluting balloons have used MEDRAD's Paccocath technology, and these new data will now provide additional information out to five years, the longest time studied among DEBs," said Jack Darby, Senior Vice President of MEDRAD Interventional. "We remain committed to further elucidating long-term clinical outcomes with the Cotavance paclitaxel eluting balloon catheter compared to or in combination with other interventional therapies through our large clinical studies and registry program. Collectively, this will include more than 1,700 patients and approximately 200 centers around the world."

MEDRAD Interventional will have an extensive presence at the 2011 TCT conference. In addition to the presentation of new five-year data, MEDRAD is supporting two symposia, Management of Thrombus in STEMI Interventions: Discussion and Debate on the Role of AngioJet Thrombectomy and Manual Aspiration (Wednesday, Nov. 9, breakfast symposium), and Long-term Clinical Data of Paccocath Technology, Preclinical Evidence, and Planned Cotavance DEB Peripheral Study Designs (Thursday, Nov. 10, luncheon symposium). The MEDRAD Interventional exhibit booth will include information on its broad range of devices and display products from Pathway Medical Technologies, a recent acquisition that places MEDRAD Interventional as an emerging leader in revascularization solutions.  

About Cotavance with Paccocath Technology

The Cotavance balloon catheter is to be used in percutaneous interventions for the treatment of peripheral arterial disease for balloon dilation of stenotic lesions in the iliac and infrainguinal arteries while applying paclitaxel to the vessel wall to inhibit restenosis. The Paccocath technology is a proprietary drug matrix applied to the balloon of an angioplasty catheter. The matrix consists of paclitaxel, long used in drug-eluting stents to treat cardiovascular disease, and a radiologic contrast agent, Ultravist® 370.(1) When the balloon is inflated to dilate the narrowed vessel, paclitaxel is delivered directly to the diseased area. The Cotavance catheter received CE Mark certification in Europe in 2011. MEDRAD Interventional is moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining FDA approval for Cotavance product in the United States.

About MEDRAD

The cardiovascular products of MEDRAD, Inc. were merged with the endovascular products of Possis Medical to form MEDRAD Interventional. Focused on the research and development of advanced technologies, MEDRAD Interventional designs, manufactures and markets devices that enable interventional physicians to better see and treat coronary and vascular disease.

MEDRAD, Inc. develops, markets and services medical devices used to diagnose and treat disease. Its product offerings include fluid injection systems for radiology and cardiology, endovascular devices for the treatment of cardiovascular disease, magnetic resonance-compatible accessories and equipment services. MEDRAD is a two-time recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence (2003 and 2010). The company's world headquarters is near Pittsburgh, Pa., in the United States. MEDRAD is a business of Bayer HealthCare. More company information is available at www.medrad.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.9 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec. 31, 2010) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) Paccocath, Cotavance and Ultravist are trademarks of Bayer Pharma AG


'/>"/>
SOURCE MEDRAD Interventional
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Phycologia ... A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested the magnitude ... pair observed that when photosynthetically active radiation (i.e. the white light in our ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every ... the most heartfelt wishes of these children. The wishes provide hope and ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization ...
(Date:5/5/2016)... ... , ... Long Island’s fastest growing comprehensive eye care provider, North Shore ... Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic coverage in ... partner of North Shore Eye Care. , “We are extremely proud to welcome ...
(Date:5/5/2016)... ... , ... TIME for Kids and The ZAC Foundation – a national leader ... nearly 1 million children with important water safety messages before summer break begins. ... accidental death in children one to 6 years of age. TIME for Kids ...
(Date:5/5/2016)... ... May 05, 2016 , ... In honor of National Nurses Week ... all over the United States to thank a nurse who's made a difference in ... $5 to the American Red Cross of San Diego/Imperial Counties (up to $10,000) every ...
Breaking Medicine News(10 mins):